VIDA Launches Cloud-Based Case Viewer
VIDA Diagnostics has released a cloud-based case viewer, designed to enhance clinical trial imaging workflows. Users of the VIDA Intelligence Platform can now view clinical trial imaging cases directly in a web browser to review imaging and clinical data. This new capability will streamline quality-controlled data curation as cases and reader impressions are added to the digital biobank.
The case viewer will have an impact on several clinical trial imaging workflows, including:
- Quality control: Members of a trial team will now have access to view the images collected, incorporating a visual quality control step into the workflow to ensure only high-quality data is added to the digital biobank.
- Eligibility reads: Radiologists can view images and assess patients’ imaging data for clinical trial eligibility. Eligibility results are made available to trial team members in real-time within the trial imaging management platform.
Reference
VIDA Launches Cloud-Based Case Viewer to Improve Clinical Trial Imaging Workflows. (2023 May, 22). Vida Diagnostics.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
